Evidence map›Paper›PMID 36980710›Full record

ArticleCancers2023

Inhibitors of the Oncogenic PA2G4-MYCN Protein-Protein Interface.

Hassina Massudi, Jie-Si Luo, Jessica K Holien, Satyanarayana Gadde, Sukriti Krishan, Mika Herath, Jessica Koach, Brendan W Stevenson, Michael A Gorman, Pooja Venkat and 5 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Hassina MassudiChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
Jie-Si LuoChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.ORCID 0000-0001-5324-1869
Jessica K HolienSchool of Science, STEM College, RMIT University, Melbourne, VIC 3000, Australia.ORCID 0000-0002-8735-2871
Satyanarayana GaddeChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
Sukriti KrishanChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
Mika HerathChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
Jessica KoachChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
Brendan W StevensonACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
Michael A GormanACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.ORCID 0000-0003-3438-8245
Pooja VenkatChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
Chelsea MayohChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.ORCID 0000-0002-6398-3046
Xue-Qun LuoDepartment of Paediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, China.
Michael W ParkerACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, VIC 3065, Australia.
Belamy B CheungChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.ORCID 0000-0001-8784-860X
Glenn M MarshallChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2750, Australia.
UNSW Sydney · AUSt Vincents Institute of Medical Research · AUSun Yat-sen University · CNThe University of Melbourne · AU

Funding

Cancer Council NSW PG-11-06Cancer Council NSW RG21-08Cancer Institute of New South Wales 10/TPG/1-13National Health and Medical Research Council APP1016699National Health and Medical Research Council APP1117183National Health and Medical Research Council APP1125171
6 · The paper itself

Abstract

MYCN is a major oncogenic driver for neuroblastoma tumorigenesis, yet there are no direct MYCN inhibitors. We have previously identified PA2G4 as a direct protein-binding partner of MYCN and drive neuroblastoma tumorigenesis. A small molecule known to bind PA2G4, WS6, significantly decreased tumorigenicity in

Indexed as

inhibitorsMYCNneuroblastomaPA2G4WS6

Identifiers

PMID36980710
PMCPMC10046377
OpenAlexW4327971693

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read54
table measurements read9
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.